Compare RELY & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | SYRE |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2021 | 2016 |
| Metric | RELY | SYRE |
|---|---|---|
| Price | $13.77 | $33.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $26.00 | ★ $56.50 |
| AVG Volume (30 Days) | ★ 2.5M | 795.0K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,544,865,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.57 | N/A |
| P/E Ratio | $145.89 | ★ N/A |
| Revenue Growth | ★ 31.27 | N/A |
| 52 Week Low | $12.08 | $10.91 |
| 52 Week High | $27.32 | $35.31 |
| Indicator | RELY | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 58.08 |
| Support Level | $13.06 | $30.00 |
| Resistance Level | $13.88 | $34.21 |
| Average True Range (ATR) | 0.41 | 1.83 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 55.07 | 84.46 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.